Mazdutide Research Peptide (IBI362 / Dual GLP-1R/GCGR Agonist)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Mazdutide (IBI362, LY3305677, OXM-3, CAS 2259884-03-0) is a synthetic long-acting oxyntomodulin analog and unimolecular dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), originally licensed from Eli Lilly and developed by Innovent Biologics, supplied by Nextday Peptides in lyophilized format for laboratory and analytical research applications. Engineered on the mammalian oxyntomodulin backbone — which contains the glucagon sequence with a C-terminal extension — Mazdutide incorporates targeted amino acid modifications and lipidation strategies to enhance enzymatic stability, albumin binding, and extend receptor engagement in experimental models. It binds human GCGR with Ki of 17.7 nM and human GLP-1R with Ki of 28.6 nM in reference binding assays. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.
Compound Specifications
| Compound Name | Mazdutide / IBI362 / LY3305677 / OXM-3 |
| Classification | Unimolecular dual GLP-1R/GCGR agonist — long-acting oxyntomodulin analog |
| Amino Acids | 39 |
| Receptor Targets | GLP-1R (Ki 28.6 nM human) + GCGR (Ki 17.7 nM human) |
| Structural Basis | Oxyntomodulin backbone with targeted modifications and fatty acid lipidation |
| CAS Number | 2259884-03-0 |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Storage | -20°C lyophilized; 2–8°C after reconstitution |
| Synonyms | IBI362, LY3305677, OXM-3, IBI-362, LY 3305677 |
| Developer | Innovent Biologics / Eli Lilly (original licensor) |
Why Research Laboratories Select Mazdutide
Mazdutide is the most clinically advanced unimolecular dual GLP-1R/GCGR agonist in current research — the first compound of this class to receive regulatory acceptance for obesity (China NMPA, 2025) and the only dual GLP-1R/GCGR agonist with completed Phase 3 trial data from the GLORY program. Its balanced GLP-1R/GCGR receptor profile makes it a uniquely valuable research tool for laboratories studying dual incretin/glucagon pathway interactions, comparative receptor pharmacology versus single-receptor GLP-1 agonists, and the metabolic biology of simultaneous GLP-1R activation (cAMP/PKA insulin secretion pathway) and GCGR activation (hepatic glucose production, energy expenditure pathway) within a single experimental system.
- Unimolecular dual GLP-1R/GCGR agonist — balanced receptor profile distinct from GLP-1 mono-agonists and GLP-1/GIP dual agonists
- Oxyntomodulin-based backbone — naturally derived structural scaffold with endogenous GLP-1R/GCGR dual activity
- Ki 17.7 nM at human GCGR and 28.6 nM at human GLP-1R — reference binding data from MedChemExpress
- Long-acting fatty acid lipidation — albumin binding for extended receptor engagement in experimental models
- First dual GLP-1R/GCGR agonist to complete Phase 3 and receive regulatory acceptance — GLORY program (China)
- Studied alongside GLP-1 mono-agonists (Semaglutide) and triple agonists (Retatrutide) for comparative receptor pathway biology
- Lyophilized format ensures stability and reproducibility across experimental runs
- Batch and lot identifiers on all labeling for full laboratory documentation compliance
Research Background
Mazdutide was originally developed by Eli Lilly as LY3305677 and subsequently licensed to Innovent Biologics for development as IBI362. Chen et al. (2022) published design and optimization data in the Journal of Medicinal Chemistry. Jiang et al. published Phase 1b randomized controlled trial data in a peer-reviewed journal establishing the GLP-1R/GCGR dual agonism profile. The GLORY-1 Phase 3 trial published 48-week data. In June 2025 Mazdutide became the world’s first GLP-1/glucagon dual receptor agonist approved for weight management, receiving regulatory acceptance from China’s NMPA. Research-grade Mazdutide supplied by Nextday Peptides is not equivalent to any approved pharmaceutical formulation. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: Chen et al. (2022) — Journal of Medicinal Chemistry | Phase 1b Trial — PMC
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before 3:30 PM ET
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- After reconstitution store at 2–8°C and use within 7 days
- Avoid repeated freeze-thaw cycles to maintain peptide and lipidation integrity
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is Mazdutide?
Mazdutide (IBI362, LY3305677, CAS 2259884-03-0) is a synthetic 39 amino acid long-acting oxyntomodulin analog and unimolecular dual agonist of GLP-1R and GCGR. Originally licensed from Eli Lilly and developed by Innovent Biologics, it is the first GLP-1R/GCGR dual agonist to receive regulatory acceptance for obesity. Supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
How does Mazdutide differ from Tirzepatide and Retatrutide?
Tirzepatide (GLP-2T) is a dual GIP/GLP-1 receptor agonist. Retatrutide (GLP-3R) is a triple GLP-1R/GIPR/GCGR agonist. Mazdutide is a dual GLP-1R/GCGR agonist without GIP receptor activity — making it the only pure GLP-1R/GCGR dual agonist available for comparative receptor pharmacology research. This distinct receptor profile makes Mazdutide an essential reference compound for laboratories studying the specific contribution of GCGR agonism to dual incretin pathway biology.
What is oxyntomodulin and why is it the basis for Mazdutide?
Oxyntomodulin is an endogenous 37 amino acid gut peptide derived from proglucagon that naturally activates both GLP-1R and GCGR simultaneously. It contains the full glucagon sequence with an 8 amino acid C-terminal extension. Mazdutide is engineered on the oxyntomodulin backbone with structural modifications that enhance enzymatic stability, extend half-life through albumin binding, and optimize the GLP-1R/GCGR potency balance for research applications.
What are the binding affinities of Mazdutide at GLP-1R and GCGR?
In reference binding assays published by MedChemExpress, Mazdutide binds human GCGR with Ki of 17.7 nM and human GLP-1R with Ki of 28.6 nM — demonstrating balanced sub-30 nM affinity at both receptor targets with slightly greater potency at GCGR.
What purity is your Mazdutide?
Every batch is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Orders placed before 3:30 PM ET are processed same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
Research-grade Mazdutide is not equivalent to any approved drug product and is not approved by the FDA for any indication. It is for laboratory research use only and is not intended for diagnostic, therapeutic, or clinical applications.
What other compounds does Nextday Peptides carry?
We also carry Retatrutide GLP-3, Tirzepatide GLP-2T, Semaglutide GLP-1, and Cagrilintide. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not FDA approved • Not equivalent to any approved drug product • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only
